After the ICU Door Closes: One in Four HIV Patients Rehospitized or Dead Within Weeks of Cryptococcal Meningitis Discharge

Surviving an initial hospital stay for cryptococcal meningitis, the most lethal AIDS-related opportunistic infection, has long been treated as the decisive turning point in a patient’s recovery. A new analysis from Uganda challenges that assumption with sobering precision. Researchers pooled data from four prospective clinical trials conducted between 2015 and 2024 at Mulago, Mbarara, and Kiruddu Hospitals and found that among 787 adults with HIV-related cryptococcal meningitis who were discharged alive, 26.6 percent—more than one in four—were either readmitted to hospital or had died within just ten weeks of leaving care. The findings, published in BMC Infectious Diseases, offer the most detailed picture yet of what happens to these patients after the hospital doors close, and they suggest that the danger window extends far beyond the acute infection itself.

The study, led by Rhona C. B. Muyise and Samuel Jjunju of the Infectious Diseases Institute at Makerere University, together with collaborators at the University of Minnesota and other institutions, was designed as a post-hoc analysis of a prospective cohort assembled from the ASTRO, AMBITION, ENACT, and FLOOR clinical trials. Of 1,055 participants diagnosed with cryptococcal meningitis across these trials, 787 survived their initial hospitalization and could be followed for more than ten weeks after discharge. This large, carefully characterized population allowed the investigators to measure not only how often rehospitalization occurred, but why it occurred and what it meant for survival—questions that have remained largely unanswered despite substantial advances in the treatment of cryptococcal disease itself.

The technical details of the cohort underscore how profoundly immunocompromised these patients were. The median CD4 cell count at baseline was just 21 cells per microliter of blood, with an interquartile range of 8 to 58—a level of immune depletion at which the body’s defenses against fungal pathogens are essentially absent. Only 45 percent of participants had prior experience with antiretroviral therapy, meaning that more than half were starting HIV treatment for the first time while simultaneously battling a life-threatening fungal infection of the brain and its surrounding membranes. Cryptococcal meningitis is caused by Cryptococcus neoformans and related species, environmental yeasts that people inhale routinely but that cause disease almost exclusively in severely immunosuppressed individuals.

The headline numbers are stark. Within ten weeks of discharge, 17 percent of the 787 survivors—133 patients—were rehospitalized at least once, and 13 percent—101 patients—died. These categories overlapped in important ways: among the 654 participants who did not report rehospitalization, 11.6 percent, or 76 patients, nevertheless died by the ten-week mark without ever returning to hospital. Among the 133 who were rehospitalized, 18 percent, or 25 patients, died during or after that readmission. The median time from initial discharge to rehospitalization was 20 days, with an interquartile range of 10 to 36 days, meaning that half of all readmissions occurred within roughly three weeks of discharge—a period when many patients in resource-limited settings have limited access to follow-up care.

Perhaps the most clinically valuable contribution of the study is its systematic accounting of why patients returned to hospital. The researchers classified the reasons for all 133 rehospitalizations and found that the largest share—92 cases—stemmed from meningitis-related causes: culture-positive relapse of the original cryptococcal infection, paradoxical immune reconstitution inflammatory syndrome, or elevated intracranial pressure. Each of these mechanisms reflects a distinct biological problem. Relapse occurs when viable fungi persist despite antifungal therapy, often because induction treatment was inadequate or adherence lapsed. Paradoxical immune reconstitution inflammatory syndrome, or IRIS, is the inflammatory storm that can erupt when antiretroviral therapy restores immune function and the revived immune system mounts an exuberant response to residual fungal antigens in the central nervous system. Elevated intracranial pressure, a hallmark of cryptococcal meningitis, can persist or recur even after microbiological cure, causing severe headaches, vision loss, and neurological deterioration that require repeated lumbar punctures to relieve.

Beyond the brain, the readmission diagnoses read like a catalogue of advanced AIDS and its complications. Tuberculosis accounted for 26 rehospitalizations, other opportunistic infections for 39, and malignancy for 9. Hematologic disorders, including anemia and cytopenias, drove 21 admissions, while kidney and electrolyte disorders—conditions that can arise from both HIV-associated nephropathy and the nephrotoxic effects of amphotericin-based antifungal regimens—accounted for 29. Another 23 admissions were attributed to other conditions. The breadth of this list is itself a finding: patients surviving cryptococcal meningitis are not merely at risk of their index infection recurring, but remain extraordinarily vulnerable to the full spectrum of AIDS-defining and treatment-related complications during the fragile weeks after discharge.

In an effort to identify who was most likely to be readmitted, the investigators performed statistical analyses of potential risk factors, and the results were unexpectedly null. No baseline characteristic reliably predicted rehospitalization. This absence of identifiable risk factors carries its own clinical message: readmission risk appears to be distributed broadly across the survivor population rather than concentrated in a recognizable high-risk subgroup. In practical terms, clinicians cannot easily single out which discharged patients warrant the most intensive follow-up on the basis of demographic or clinical features alone, which argues for structured post-discharge monitoring for all survivors rather than targeted surveillance of a presumed vulnerable minority.

Where the analysis did find signal was in mortality. Older age was associated with an increased risk of death during the post-discharge period, while two factors were protective: higher body weight and higher Glasgow Coma Scale scores at baseline. The Glasgow Coma Scale, a standard measure of consciousness and neurological function, is already used to stratify severity in cryptococcal meningitis, and its protective association here confirms that patients discharged with better neurological status fare better. The protective effect of higher weight likely reflects overall nutritional reserve and illness severity—patients who are more wasted by advanced HIV disease and prolonged infection have less physiological buffer against subsequent complications. These mortality associations, unlike the rehospitalization analysis, offer concrete variables that clinicians can incorporate into discharge counseling and triage decisions.

The study’s implications reach well beyond Uganda. Cryptococcal meningitis kills an estimated 180,000 people annually worldwide, with the overwhelming burden in sub-Saharan Africa, and even with newer, more effective and better-tolerated regimens such as the single-dose amphotericin strategy validated in the AMBITION trial, survival after hospital discharge has remained poorly characterized. By demonstrating that a quarter of survivors experience rehospitalization or death within ten weeks, the study reframes the post-discharge period as a distinct phase of care deserving its own clinical infrastructure—structured follow-up visits, early antiretroviral therapy initiation with careful IRIS monitoring, screening for tuberculosis and other opportunistic infections, and management of intracranial pressure. The work also highlights the value of linking large clinical trial cohorts to longitudinal outcomes: because the four trials enrolled participants prospectively with standardized follow-up, the researchers could capture readmissions and deaths with a completeness that routine hospital records rarely allow.

For a disease that has seen genuine therapeutic progress over the past decade, the persistence of this post-discharge crisis is a reminder that antifungal drug regimens, however improved, address only part of the problem. The patients in this cohort left the hospital with CD4 counts in the low double digits, often newly started on antiretroviral therapy, and facing a landscape of competing infectious, inflammatory, renal, hematologic, and malignant threats. The Ugandan team’s data make clear that the ten weeks after discharge are not a quiet convalescence but a high-stakes transition, and that health systems serving populations with advanced HIV disease must plan for it accordingly. Whether interventions such as enhanced follow-up clinics, pre-emptive treatment of residual fungal burden, or earlier detection of IRIS and tuberculosis can bend this curve is now the pressing question the study leaves for the field.

Subject of Research: Rehospitalization and post-discharge outcomes among adults with HIV-related cryptococcal meningitis in Uganda

Article Title: Incidence, reasons, and outcomes of rehospitalization among adults with HIV-related cryptococcal meningitis in Uganda: a post-hoc analysis of a prospective cohort

Article References: Muyise, R. C. B., Jjunju, S., Kwizera, R., Dai, B., Adzemovic, T., Mufti, S. S., Meya, D. B., & Boulware, D. R. (2026). Incidence, reasons, and outcomes of rehospitalization among adults with HIV-related cryptococcal meningitis in Uganda: a post-hoc analysis of a prospective cohort. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14594-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14594-8

Keywords: cryptococcal meningitis, HIV, AIDS, rehospitalization, mortality, Uganda, immune reconstitution inflammatory syndrome, tuberculosis, intracranial pressure, CD4 count, antiretroviral therapy, BMC Infectious Diseases